Get FREE U.S. Shipping on $75 Orders*

Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in children.

1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)



A recombinant lipoprotein vaccine against
Lyme disease, containing 30 microg of Borrelia burgdorferi outer surface protein A (OspA) with aluminum adjuvant, has been shown in a large US field trial of subjects >/=15 years of age to offer 76% efficacy against clinical
Lyme disease after 3 injections given at 0, 1, and 12 months.
Lyme disease is also an important problem in children; thus, OspA vaccine trials in children are needed. The purpose of this study was to investigate the safety and immunogenicity of 2 different doses of lipoprotein OspA with aluminum adjuvant vaccine in healthy children 5 to 15 years of age in a double-blind, randomized study.


In a double-blind study, 250 children from the Czech Republic were randomly assigned to receive 15 microg or 30 microg of OspA vaccine at 0, 1, and 2 months. Serum samples, obtained before vaccination and 1 month after the second and third doses, were analyzed for antiOspA antibody. Solicited and unsolicited symptoms were collected from diary cards.


Local pain at the injection site was reported by approximately 76% of the 250 children. Headaches (after 5% to 18% of the injections) and malaise (after 2% to 16% of the injections) were the most frequently reported general symptoms. Local and generalized symptoms were not different between the 15 microg and 30 microg groups, and all symptoms resolved within 4 days. Both doses were highly immunogenic, with the 30 microg dose eliciting higher antibody levels. Seroconversion occurred in 99% of the 250 children.


The OspA vaccine against
Lyme disease was well tolerated and highly immunogenic in children.

J Pediatr. 1999 Nov;135(5):575-9. Clinical Trial; Randomized Controlled Trial

ProHealth CBD Store


1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)

Leave a Reply